172 related articles for article (PubMed ID: 38073770)
1. Renal cell carcinoma associated with Xp11.2 translocation/transcription factor E3 gene fusion: A case report and literature review.
Yang D; Tang W; Liu M; Xie Z; Shi F; Zhao Z; Yang X; Wu T
Oncol Lett; 2024 Jan; 27(1):29. PubMed ID: 38073770
[TBL] [Abstract][Full Text] [Related]
2. Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion: A case report.
Pan X; Quan J; Zhao L; Li W; Wei B; Yang S; Lai Y
Mol Clin Oncol; 2018 Jan; 8(1):83-85. PubMed ID: 29399348
[TBL] [Abstract][Full Text] [Related]
3. Bilateral Xp11.2 translocation renal cell carcinoma: a case report.
Karashima T; Kuno T; Kuroda N; Satake H; Fukata S; Chikazawa M; Kawada C; Yamasaki I; Shuin T; Hiroi M; Inoue K
BMC Urol; 2018 Nov; 18(1):106. PubMed ID: 30458744
[TBL] [Abstract][Full Text] [Related]
4. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
5. Xp11.2 Translocation Renal Cell Carcinoma With
Ge Y; Lin X; Zhang Q; Lin D; Luo L; Wang H; Li Z
Front Oncol; 2021; 11():784993. PubMed ID: 34917511
[TBL] [Abstract][Full Text] [Related]
6. Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.
Yu W; Wang Y; Rao Q; Jiang Y; Zhang W; Li Y
Pathol Res Pract; 2019 Sep; 215(9):152521. PubMed ID: 31277953
[TBL] [Abstract][Full Text] [Related]
7. Renal cell carcinoma associated with Xp11.2 translocation/transcription factor E3 gene fusion: an adult case report and literature review.
Wang Y; Wang Y; Feng M; Lian X; Lei Y; Zhou H
J Int Med Res; 2020 Oct; 48(10):300060520942095. PubMed ID: 33026261
[TBL] [Abstract][Full Text] [Related]
8. Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma with a micropapillary pattern: cases report and literature review.
Xu ZY; Wang JP; Zhang Y; Wu SW; Ma L; Qin YZ; Wang ZP; Chai DM; Tao YS
Am J Transl Res; 2019; 11(1):327-339. PubMed ID: 30787990
[TBL] [Abstract][Full Text] [Related]
9. Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion in the elderly: case report and literature review.
Masago T; Kobayakawa S; Ohtani Y; Taniguchi K; Naka T; Kuroda N; Takahashi C; Isoyama T; Sejima T
Int Cancer Conf J; 2020 Oct; 9(4):182-186. PubMed ID: 32903928
[TBL] [Abstract][Full Text] [Related]
10. An Xp11.2 translocation renal cell carcinoma with SMARCB1 (INI1) inactivation in adult end-stage renal disease: a case report.
Yu L; Li J; Xu S; Navia Miranda M; Wang G; Duan Y
Diagn Pathol; 2016 Oct; 11(1):98. PubMed ID: 27733182
[TBL] [Abstract][Full Text] [Related]
11. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
[TBL] [Abstract][Full Text] [Related]
12. The incidence of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion in Saudi adult patients with renal cancer: a retrospective tissue microarray analysis.
Al-Maghrabi J; Mufti S; Gomaa W
Pol J Pathol; 2018; 69(4):376-383. PubMed ID: 30786687
[TBL] [Abstract][Full Text] [Related]
13. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.
Chen X; Yang Y; Gan W; Xu L; Ye Q; Guo H
Medicine (Baltimore); 2015 May; 94(19):e873. PubMed ID: 25984679
[TBL] [Abstract][Full Text] [Related]
14. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
15. A case of bilateral renal cell carcinoma associated with long-term dialysis showing false-positive immunoreactivity for TFE3 as Xp11 translocation renal cell carcinoma.
Kurisaki-Arakawa A; Saito T; Takahashi M; Mitani K; Fukumura Y; Nagashima Y; Argani P; Yao T
Int J Clin Exp Pathol; 2013; 6(11):2585-90. PubMed ID: 24228124
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of a break-apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma.
Kim SH; Choi Y; Jeong HY; Lee K; Chae JY; Moon KC
Virchows Arch; 2011 Sep; 459(3):299-306. PubMed ID: 21773754
[TBL] [Abstract][Full Text] [Related]
17. Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma.
Pradhan D; Roy S; Quiroga-Garza G; Cieply K; Mahaffey AL; Bastacky S; Dhir R; Parwani AV
Diagn Pathol; 2015 Sep; 10():179. PubMed ID: 26415891
[TBL] [Abstract][Full Text] [Related]
18. Contrast-enhanced ultrasound findings of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma.
Wei S; Tian F; Xia Q; Huang P; Zhang Y; Xia Z; Wu M; Yang B
Cancer Imaging; 2019 Dec; 20(1):1. PubMed ID: 31892340
[TBL] [Abstract][Full Text] [Related]
19. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Clinical complete response of advanced renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion by treated by camrelizumab and axitinib: A rare case report.
Zhao J; Dai K; Xie J; Fang C; Chen N; Dai J; Xu D
Front Pharmacol; 2022; 13():927299. PubMed ID: 36034832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
